Cellebrite DI (NASDAQ:CLBT) Given New $12.50 Price Target at Needham & Company LLC

Cellebrite DI (NASDAQ:CLBT) had its price target lowered by Needham & Company LLC from $15.00 to $12.50 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s target price would indicate a potential upside of 15.74% from the stock’s previous close.

Several other equities research analysts have also commented on CLBT. DA Davidson boosted their price target on Cellebrite DI from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $21.30.

Cellebrite DI Stock Down 29.2%

NASDAQ:CLBT opened at $10.80 on Friday. Cellebrite DI has a fifty-two week low of $9.58 and a fifty-two week high of $19.98. The stock has a market cap of $2.69 billion, a PE ratio of 38.57, a price-to-earnings-growth ratio of 1.89 and a beta of 1.18. The firm’s fifty day simple moving average is $14.52 and its 200-day simple moving average is $14.05.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.05 by $0.06. The firm had revenue of $131.14 million during the quarter, compared to analysts’ expectations of $131.87 million. Cellebrite DI had a net margin of 14.48% and a return on equity of 18.38%. Equities analysts anticipate that Cellebrite DI will post 0.41 earnings per share for the current year.

Insider Transactions at Cellebrite DI

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO David Barter sold 41,734 shares of the business’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the transaction, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at approximately $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 297,934 shares of company stock valued at $4,631,972 in the last ninety days. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Roubaix Capital LLC raised its holdings in shares of Cellebrite DI by 108.1% in the 1st quarter. Roubaix Capital LLC now owns 303,215 shares of the company’s stock worth $4,178,000 after purchasing an additional 157,536 shares during the period. Principal Financial Group Inc. lifted its position in Cellebrite DI by 33.9% during the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock valued at $29,712,000 after buying an additional 545,334 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in Cellebrite DI during the first quarter worth approximately $2,134,000. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Cellebrite DI by 28.6% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,350,000 shares of the company’s stock worth $24,341,000 after acquiring an additional 300,000 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Cellebrite DI by 14.7% in the 1st quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock valued at $39,420,000 after acquiring an additional 365,700 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

Key Stories Impacting Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite reported second-quarter adjusted EPS of $0.11, above the $0.05 consensus estimate cited by MarketBeat, while subscription revenue continued to rise. Management also raised its adjusted EBITDA target. Cellebrite second-quarter earnings report
• Positive Sentiment: D.A. Davidson maintained its Buy rating, and one analyst argued that the selloff may be excessive relative to Cellebrite’s longer-term growth opportunity. D.A. Davidson rating
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, substantially above average volume, suggesting some traders were positioning for a rebound, although this is speculative rather than a fundamental catalyst.
• Neutral Sentiment: Cellebrite announced a planned CEO succession, with Shiven Ramji replacing Thomas E. Hogan effective August 13. The transition could bring a new strategic direction, but investors may initially view leadership change as an uncertainty. Cellebrite CEO succession announcement
• Negative Sentiment: The main pressure came from lowered guidance: third-quarter revenue was projected at $145 million-$148 million versus a $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million fell short of the $568.1 million estimate. The company also lowered its full-year ARR outlook, indicating weaker near-term growth than previously expected. Cellebrite 2026 outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million slightly missed the $131.87 million estimate, and another earnings estimate placed EPS at $0.11 versus $0.12 expected. The combination of an ARR miss and weaker outlook outweighed the reported EPS beat. Cellebrite investigation notice
• Negative Sentiment: Several law firms announced investigations into possible securities-law violations and the accuracy of Cellebrite’s prior projections and disclosures. These are allegations, not findings, but they add legal and reputational risk after the selloff. Kaplan Fox investigation notice
• Negative Sentiment: CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, a 15% reduction in his position. Although the sale may be related to the leadership transition or personal financial planning, its timing can weigh on sentiment. SEC insider trading filing

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.